Status:
NOT_YET_RECRUITING
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Conditions:
Advanced Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with...
Eligibility Criteria
Inclusion
- Voluntarily participate in the clinical trial, understand and sign the informed consent form, and agree to comply with the requirements specified in the protocol.
- Age ≥ 18 years.
- Female subjects must be postmenopausal and meet the trial requirements.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- Life expectancy ≥ 3 months.
- Histologically or cytologically confirmed breast cancer.
- Based on the most recent biopsy results of primary or metastatic tumor tissue, immunohistochemistry (IHC) confirms ER-positive status and HER-2-negative status.
- At least one measurable target lesion according to RECIST v1.1.
- Adequate bone marrow function within 2 weeks (14 days) prior to the initiation of study treatment, without the need for transfusion or growth factor (G-CSF, EPO, TPO, etc.) support.
- Adequate liver function.
- Renal function: serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (Ccr) \> 30 mL/min, with no significant electrolyte imbalances that are difficult to correct.
- Coagulation function: International Normalized Ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
Exclusion
- Presence of symptomatic visceral disease or any other condition deemed unsuitable for endocrine therapy as per the investigator's judgment.
- Presence of unresolved toxicities from prior therapy that have not recovered to ≤ CTCAE grade 1, excluding alopecia (any grade) or other toxicities considered by the investigator to pose no safety risk.
- Received anti-tumor drug therapy within the specified time window prior to the first dose of the investigational drug.
- Prior treatment with an experimental SERD or experimental ER antagonist.
- Received radiotherapy within 4 weeks prior to the first dose of the investigational drug.
- Used a strong CYP3A4 inhibitor within 7 days or 5 half-lives (whichever is longer) prior to the first dose.
- Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has not recovered from significant side effects, or has significant traumatic injury, non-healing wounds, or fractures.
- History of other active malignancies within 5 years prior to the first dose of the investigational drug.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Inability to swallow the formulation, or gastrointestinal impairment/disease that may affect adequate absorption of the investigational drug.
- Known clinically significant liver disease, including Child-Pugh class B or C, active viral hepatitis, or other hepatitis.
- Current documented grade 1 or higher pneumonitis or interstitial lung disease.
- Clinically significant pleural effusion, ascites, or pericardial effusion, defined as detectable on examination and requiring drainage within the past 2 weeks or additional medication to control symptoms.
- Clinically significant uncontrolled cardiac disease and/or recent cardiac events.
- History of bleeding tendency, thrombosis, or tumor embolism.
- Planned treatment with everolimus and presence of uncontrolled diabetes despite adequate therapy.
- Allergy to any of the investigational medicinal products or their components.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT07173556
Start Date
September 1 2025
End Date
October 1 2028
Last Update
September 15 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.